PDF herunterladen
Thromb Haemost 2006; 95(06): 1042-1043
DOI: 10.1160/TH05-12-0808
Letters to the Editor
Schattauer GmbH

Overcoming aspirin resistance: Increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease

Shen Wong
1   Department of Vascular Surgery, Sydney, Australia
,
Marie-Christine Morel-Kopp
2   Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, St Leonard’s, Sydney, Australia
3   Northern Blood Research Centre, Sydney University, Sydney, Australia
,
Qiang Chen
2   Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, St Leonard’s, Sydney, Australia
3   Northern Blood Research Centre, Sydney University, Sydney, Australia
,
Michael Appleberg
1   Department of Vascular Surgery, Sydney, Australia
,
Christopher M. Ward
2   Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, St Leonard’s, Sydney, Australia
3   Northern Blood Research Centre, Sydney University, Sydney, Australia
,
David R. Lewis
4   Department of Surgery, Christchurch Hospital, Christchurch, New Zealand
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 20. Dezember 2005

Accepted after resubmission 08. Mai 2006

Publikationsdatum:
30. November 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

 

 

  • References

  • 1 Cassar K, Bachoo P, Brittenden J. The role of platelets in peripheral vascular disease. EurJ Vasc Endovasc Surg 2003; 25: 6-15.
    PubMedSuche in Google Scholar
  • 2 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
    CrossrefPubMedSuche in Google Scholar
  • 3 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
    CrossrefPubMedSuche in Google Scholar
  • 4 Wong S, Appleberg M, Ward C. et al. Aspirin resistance in cardiovascular disease: A review. Eur J Vasc Endovasc Surg 2004; 27: 456-65.
    CrossrefPubMedSuche in Google Scholar
  • 5 Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-17.
    CrossrefPubMedSuche in Google Scholar
  • 6 Gum PA, Kottke-Marchant K, Poggio ED. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.[see comment]. Am J Cardiol 2001; 88: 230-5.
    CrossrefPubMedSuche in Google Scholar
  • 7 Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand’s disease and other disorders. AmJ Hematol 1999; 62: 165-74.
    PubMedSuche in Google Scholar
  • 8 Hung J, Lam JY, Lacoste L. et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-6.
    CrossrefPubMedSuche in Google Scholar
  • 9 Chakroun T, Gerotziafas G, Robert F. et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. BrJ Haematol 2004; 124: 80-5.
    CrossrefPubMedSuche in Google Scholar
  • 10 Yusuf S, Zhao F, Mehta SR. et al. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
    CrossrefPubMedSuche in Google Scholar
  • 11 Perneby C, Wallen NH, Rooney C. et al. Doseand time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-8.
    Thieme ConnectPubMedSuche in Google Scholar